|Bid||8.1700 x 1300|
|Ask||8.1000 x 800|
|Day's Range||7.8700 - 8.2500|
|52 Week Range||4.7500 - 21.5900|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.40|
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.
Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint of significantly reducing triglyceride levels in Severe Hypertriglyceridemia (or SHTG) patients with baseline serum triglyceride levels greater than 500 mg/dl. The drug also demonstrated a solid safety and tolerability profile and could be safely combined with other drugs. Gemcabene currently holds a method patent in SHTG indication valid until 2032. ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Foot Locker, Inc. (NYSE: FL ) stock was trading higher ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 28) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aptinyx Inc (NASDAQ: ...
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / It was a huge day for Gemphire Therapeutics on Thursday, skyrocketing over 120% in after-hours trading on the announcement that the company had achieved its primary endpoint in its Phase 2b INDIGO-1 trial in SHTG in patients with baseline serum TGs 500 mg/dL. Shares of Teva Pharmaceuticals saw gains after announcing that the company would be presenting new data for its migraine drug Fremanezumab at the AHS's (American Headache Society) 60th Annual Scientific Meeting in San Francisco. Teva Pharmaceutical Industries Limited shares closed up 4.53% yesterday on roughly 14.8 million shares traded.
Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH), today announced that it achieved the primary endpoint, reduction of TGs by gemcabene, in its Phase 2b INDIGO-1 trial in SHTG patients with baseline serum TGs 500 mg/dL.
Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and dyslipidemia, is sponsoring via an educational grant the American Liver Foundation’s (ALF) upcoming webinar "Pediatric Non-Alcoholic Fatty Liver Disease—Yes, It Absolutely Starts in Childhood” on Wednesday, May 23. The American Liver Foundation is a non-profit organization that facilitates, advocates, and promotes education, support, and research for the prevention, treatment, and cure of liver disease.
I am going to take a deep dive into Gemphire Therapeutics Inc’s (NASDAQ:GEMP) most recent ownership structure, not a frequent subject of discussion among individual investors. The impact of aRead More...
LIVONIA, Mich., May 08, 2018-- Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including non-alcoholic ...
Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), today announced the appointment of Steven Gullans, Ph.D., as its President and Chief Executive Officer, effective immediately. Dr. Gullans has been Interim President and Chief Executive Officer since May 2017. He has almost 30 years of experience advising, co-founding and investing in biotech companies across many fields including cardiovascular disease.
Gemphire Therapeutics Inc’s (NASDAQ:GEMP): Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitisRead More...
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
Interim President & CEO of Gemphire Therapeutics Inc (NASDAQ:GEMP) Steven R. Ph.d. Gullans bought 71,429 shares of GEMP on 02/08/2018 at an average price of $7 a share.
The latest earnings release Gemphire Therapeutics Inc’s (NASDAQ:GEMP) announced in September 2017 signalled that losses became smaller relative to the prrior year’s level – great news for investors Investors mayRead More...